Omeros Corp (OMER) · Oct 30, 2026 · Other events

Omeros executive option adds $25-$40 hurdles, but share count is unclear

Performance option grant — Four hurdles: $25, $30, $35 and $40

Omeros filed an executive compensation grant for Gregory Demopulos with four stock-price hurdles, adding alignment but leaving dilution unclear.

Omeros is moving from development-stage biotech toward commercial execution around YARTEMLEA, its FDA-approved treatment for transplant-associated thrombotic microangiopathy, while advancing additional complement, oncology and addiction programs. The filing puts CEO Gregory A. Demopulos on a performance-based equity plan. The exercise notice identifies Demopulos as the purchaser, and the option is split into four equal tranches tied to 30-trading-day VWAP hurdles of $25, $30, $35 and $40. 〔0〕

The structure is meaningfully performance-linked, but not a clean near-term operating signal. Each tranche requires continued service and vests gradually over four years—25% after the first anniversary, then monthly—so the award is designed to retain management and tie part of its value to sustained shareholder performance rather than simply handing over immediately exercisable equity.

The main limitation is missing scale. The supplied filing content does not state the number of option shares or the exercise price, so investors cannot quantify potential dilution or the award’s economic value from this disclosure alone. The filing also provides change-in-control treatment: hurdles are deemed satisfied only for tranches matching consideration of at least the relevant threshold, while lower-value tranches are forfeited.

Bottom line: This is a new alignment and retention mechanism for Omeros’ CEO, not a change to the company’s operating outlook. It is mildly constructive in design, but the undisclosed grant size keeps the economic impact—and any dilution concern—uncertain.

Original filing on SEC EDGAR

More Omeros Corp news

Omeros executive option adds $25-$40 hurdles, but share count is unclear | OMER Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.